Cargando…

Treatment Dosing Patterns and Clinical Outcomes for Patients with Type 2 Diabetes Starting or Switching to Treatment with Insulin Glargine (300 Units per Milliliter) in a Real-World Setting: A Retrospective Observational Study

INTRODUCTION: Usage patterns and effectiveness of a longer-acting formulation of insulin glargine at a strength of 300 units per milliliter (Gla-300) have not been studied in real-world clinical practice. This study evaluated differences in dosing and clinical outcomes before and after Gla-300 treat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gupta, Shaloo, Wang, Hongwei, Skolnik, Neil, Tong, Liyue, Liebert, Ryan M., Lee, Lulu K., Stella, Peter, Cali, Anna, Preblick, Ronald
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2018
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5778176/ https://www.ncbi.nlm.nih.gov/pubmed/29313285 http://dx.doi.org/10.1007/s12325-017-0651-3

Ejemplares similares

Real-World Persistence, Adherence, Hypoglycemia, and Health Care Resource Utilization in People With Type 2 Diabetes Who Continued With the Second-Generation Basal Insulin Analog Insulin Glargine 300 Units/mL or Switched to a First-Generation Basal Insulin (Insulin Glargine 100 Units/mL or Detemir 100)
por: Edelman, Steven, et al.
Publicado: (2023)

Mobile platform for rapid sub–picogram-per-milliliter, multiplexed, digital droplet detection of proteins
por: Yelleswarapu, Venkata, et al.
Publicado: (2019)

An origami paper-based nanoformulated immunosensor detects picograms of VEGF-C per milliliter of blood
por: Sun, Shuai, et al.
Publicado: (2021)

Clinical outcomes in real‐world patients with type 2 diabetes switching from first‐ to second‐generation basal insulin analogues: Comparative effectiveness of insulin glargine 300 units/mL and insulin degludec in the DELIVER D+ cohort study
por: Sullivan, Sean D., et al.
Publicado: (2018)

Reduced Hypoglycemia Risk in Type 2 Diabetes Patients Switched to/Initiating Insulin Glargine 300 vs 100 U/ml: A European Real-World Study
por: Escalada, Javier, et al.
Publicado: (2020)

Glycaemic control and hypoglycaemia in people with type 2 diabetes switching from twice‐daily basal insulin to once‐daily insulin glargine 300 U/mL or insulin glargine 100 U/mL (EDITION 1 and EDITION 2 subgroup analysis)
por: Roussel, Ronan, et al.
Publicado: (2017)

Tissue plasminogen activator (tPA) in the management of predominantly hemorrhagic age-related macular degeneration, milligram/milliliter or microgram/milliliter?
por: Boone, Niels Willem, et al.
Publicado: (2012)

Association of hypoglycaemia severity with clinical, patient‐reported and economic outcomes in US patients with type 2 diabetes using basal insulin
por: Meneghini, Luigi F., et al.
Publicado: (2018)

Low Blood Glucose Index and Hypoglycaemia Risk: Insulin Glargine 300 U/mL Versus Insulin Glargine 100 U/mL in Type 2 Diabetes
por: Kovatchev, Boris, et al.
Publicado: (2020)

Real-World Effectiveness of Insulin Glargine 300 Initiation in Switzerland
por: Thomann, Robert, et al.
Publicado: (2020)

Synthetic Mimics of Bacterial Lipid A Trigger Optical Transitions in Liquid Crystal Microdroplets at Ultralow Picogram-per-Milliliter Concentrations
por: Carter, Matthew C. D., et al.
Publicado: (2015)

Glycaemic goal attainment and hypoglycaemia outcomes in type 2 diabetes patients initiating insulin glargine 300 units/mL or 100 units/mL: Real‐world results from the DELIVER Naïve cohort study
por: Bailey, Timothy S., et al.
Publicado: (2019)

Investigational new insulin glargine 300 U/ml has the same metabolism as insulin glargine 100 U/ml
por: Steinstraesser, A, et al.
Publicado: (2014)

rDNA insulin glargine U300 – a critical appraisal
por: Wang, Fei, et al.
Publicado: (2016)

Efficacy and Safety of Switching Patients Inadequately Controlled on Basal Insulin to Insulin Glargine 300 U/mL: The TRANSITION 2 Study
por: Gourdy, Pierre, et al.
Publicado: (2019)

Switching to insulin glargine 300 units/mL in real‐world older patients with type 2 diabetes (DELIVER 3)
por: Bailey, Timothy S., et al.
Publicado: (2019)

Stop spoon dosing: milliliter instructions reduce inclination to spoon dosing
por: van Ittersum, Koert, et al.
Publicado: (2016)

Glycaemic Control in People with Type 2 Diabetes Mellitus Switching from Basal Insulin to Insulin Glargine 300 U/ml (Gla-300): Results from the REALI Pooled Database
por: Müller-Wieland, Dirk, et al.
Publicado: (2023)

Insulin Glargine 300 U/mL and Insulin Glulisine Treatment in Patients with Type 2 Diabetes: A Non-Interventional Study of Effectiveness in Routine Clinical Practice
por: Hidvégi, Tibor, et al.
Publicado: (2020)

Nocturnal Glycemic Control with New Insulin Glargine 300 U/mL
por: Yu, Neng Chun
Publicado: (2019)

Impact of Switching from Twice-Daily Basal Insulin to Once-Daily Insulin Glargine 300 U/mL in People with Type 1 Diabetes on Basal–Bolus Insulin: Phase 4 OPTIMIZE Study
por: Mathieu, Chantal, et al.
Publicado: (2020)

Spermatogenesis recovery treatment in less than four months from zero to almost 16 million sperms per milliliter after several cycles of steroids in 44‐year‐old healthy man
por: Injac, Rade
Publicado: (2023)

Erratum to: Stop spoon dosing: milliliter instructions reduce inclination to spoon dosing
por: van Ittersum, Koert, et al.
Publicado: (2016)

Asymmetric Membrane for Digital Detection of Single Bacteria in Milliliters of Complex Water Samples
por: Lin, Xingyu, et al.
Publicado: (2018)

Efficacy and Safety of Switching from Insulin Glargine 100 U/mL to the Same Dose of Glargine 300 U/mL in Japanese Type 1 and 2 Diabetes Patients: A Retrospective Analysis
por: Nakanishi, Shuhei, et al.
Publicado: (2018)

Insulin depot absorption modeling and pharmacokinetic simulation with insulin glargine 300 U/mL
por: Lindauer, Klaus, et al.
Publicado: (2019)

Potential Formula for the Calculation of Starting and Incremental Insulin Glargine Doses: ALOHA Subanalysis
por: Kadowaki, Takashi, et al.
Publicado: (2012)

Hypoglycaemia and treatment patterns among insulin‐treated patients with type 2 diabetes who switched to insulin glargine 300 units/mL versus other basal insulin in a real‐world setting
por: Zhou, Fang L., et al.
Publicado: (2019)

Analysis of α- and β-amanitin in Human Plasma at Subnanogram per Milliliter Levels by Reversed Phase Ultra-High Performance Liquid Chromatography Coupled to Orbitrap Mass Spectrometry
por: Bambauer, Thomas P., et al.
Publicado: (2020)

Low within- and between-day variability in exposure to new insulin glargine 300 U/ml
por: Becker, R H A, et al.
Publicado: (2015)

Insulin glargine 300 U/mL in the management of diabetes: clinical utility and patient perspectives
por: de Galan, Bastiaan E
Publicado: (2016)

Insulin Glargine 300 U/mL Therapy in Children and Adolescents with Type 1 Diabetes
por: Maffeis, Claudio, et al.
Publicado: (2022)

Insulin glargine 300 units/mL for the treatment of individuals with type 2 diabetes in the real world: A review of the DELIVER programme
por: Blonde, Lawrence, et al.
Publicado: (2021)

Controlling glycemic variability in people living with type 1 diabetes receiving insulin glargine 300 U/mL (Gla-300)
por: Mader, Julia K, et al.
Publicado: (2022)

The effect of concomitant DPPIVi use on glycaemic control and hypoglycaemia with insulin glargine 300 U/mL (Gla-300) versus insulin glargine 100 U/mL (Gla-100) in people with type 2 diabetes: A patient-level meta-analysis of EDITION 2 and 3
por: Yale, Jean-François, et al.
Publicado: (2018)

Clinical Outcomes of Switching to Insulin Glargine 300 U/ml from Other Basal Insulins in People with Type 2 Diabetes in Italy: A Real-World Study
por: Ragonese, Mauro, et al.
Publicado: (2020)

Insulin degludec and insulin glargine 300 U/mL: Which of these two insulins causes less hypoglycemia?
por: Buscemi, Silvio, et al.
Publicado: (2019)

Correction: Potential Formula for the Calculation of Starting and Incremental Insulin Glargine Doses: ALOHA Subanalysis
Publicado: (2014)

Correction: Potential Formula for the Calculation of Starting and Incremental Insulin Glargine Doses: ALOHA Subanalysis
Publicado: (2014)

Glycaemic control and hypoglycaemia during 12 months of randomized treatment with insulin glargine 300 U/mL versus glargine 100 U/mL in people with type 1 diabetes (EDITION 4)
por: Home, Philip D., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_v3e33i1v487eidf49t18et82qn